Promethazine Hydrochloride Injection shortage
Promethazine Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 10 affected products. The reported reason: Demand increase for the drug; Other. This page was last refreshed from FDA data on Oct 2, 2026.
Promethazine hydrochloride injection has been in shortage for over a year due to high demand. Both the 25 mg/mL and 50 mg/mL strengths still have available supply listed, though amounts are limited and more stock from Hikma is expected around October 2026.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Promethazine Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 22, 2026Currently in shortage10 of 10 products affected.
-
Sep 18, 2026FDA refreshed this shortage record8 products updated.
-
Nov 21, 2023First reported to the FDA10 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 8 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35) | — | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
| Current | Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25) | — | Unavailable | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
| Current | Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25) | — | Limited Availability | Estimated recovery: TBD | Demand increase for the drug |
| Current | Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35) | — | Available | Limited availability | Demand increase for the drug |
| Current | Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25) | — | Unavailable | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | Other |
| Current | Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25) | — | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
| Current | Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25) | — | Unavailable | Estimated recovery: TBD | Other |
Manufacturer: XGen Pharmaceuticals DJB, Inc. 📞 866-390-4411 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3) | — | Available | — | — |
| Current | Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6) | — | Unvailable | Estimated recovery: TBD | Demand increase for the drug |
These rows are manufacturer reports to the FDA for Promethazine Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Promethazine Hydrochloride Injection? options further down this page.
Why is Promethazine Hydrochloride Injection in shortage?
Promethazine hydrochloride injection is on the shortage list primarily because more people need it right now than manufacturers can keep up with — what the FDA calls a "demand increase." This is affecting products from two manufacturers, Hikma Pharmaceuticals USA and XGen Pharmaceuticals.
Here's a quick look at where things stand with Hikma's supply:
- 25 mg/1 mL (NDC 0641-0928-25): Currently unavailable; Hikma says additional lots should be ready around October 2026.
- 25 mg/1 mL (NDC 0641-1495-35): Technically available, but only in limited supply.
- 50 mg/1 mL (NDC 0641-0929-25): Limited availability, with no firm recovery date yet.
- 50 mg/1 mL (NDC 0641-1496-35): Available, with more lots scheduled to be manufactured and released as they're ready.
- Several Phenergan-branded 25 mg and 50 mg vials are currently unavailable, with no firm recovery date given for some, and additional lots being scheduled for others.
For XGen, their 50 mg/1 mL is unavailable with no firm recovery date, while their 25 mg/1 mL is currently available. It's worth noting that for some of the unavailable products, the manufacturer listed "Other" as a contributing reason alongside demand, but didn't share any additional specifics publicly.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Promethazine Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Promethazine Hydrochloride Injection?
Promethazine hydrochloride injection is currently on the FDA shortage list. If you or someone you care for uses this medicine, both strengths still have a supply source, so it should be possible to find.
Here is how the strengths look right now. The 25 mg/1 mL and 50 mg/1 mL strengths both still have an available source — no strength is completely without supply at this time. Some specific product lots are marked unavailable or limited, which is why your pharmacy may have to look for a particular version, but the medicine itself is being supplied by both makers on this record.
The reported reason is an increase in demand, along with "other" factors. This shortage has lasted over a year, and some lots are listed with recovery dates that are still to be determined, while additional 25 mg/1 mL lots are expected around October 2026.
Here is what I suggest:
- Do not stop, skip, or change any dose on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and both manufacturers for available lots.
- The same medicine is also made by Hikma in both strengths, so your pharmacy may be able to source one of those, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national data and may not match local stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Promethazine Hydrochloride Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Promethazine Hydrochloride Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Promethazine Hydrochloride | PROMETHAZINE HYDROCHLORIDE 25 mg/mL | Injection · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-0948-35 |
| Promethazine Hydrochloride | PROMETHAZINE HYDROCHLORIDE 50 mg/mL | Injection · Intramuscular | Hikma Pharmaceuticals USA Inc. | 00641-0949-35 |
Alternative dosage forms of Promethazine Hydrochloride
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 10 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Promethazine Hydrochloride 50 mg/mL | Hikma | 25 ampules | $2.339 | AP | Discontinued |
| Promethazine Hydrochloride 50 mg/mL | Hikma | 25 ampules | $2.339 | AP | Discontinued |
| Promethazine Hydrochloride 50 mg/mL | XGen | 25 ampules | $2.339 | AP | Availability likely |
| Promethazine Hydrochloride 50 mg/mL | Henry | 1 ampule | — | AP | FDA listed |
| Promethazine Hydrochloride 50 mg/mL | Hikma | 25 vials | — | AP | FDA listed |
| Promethazine Hydrochloride 50 mg/mL | Hikma | 25 vials | — | AP | FDA listed |
| Phenergan 50 mg/mL | Hikma | 25 ampules | — | AP | Discontinued |
| Phenergan 50 mg/mL | Hikma | 25 vials | — | AP | FDA listed |
| Promethazine Hydrochloride 50 mg/mL | A-S | 25 vials | — | AP | FDA listed |
| Promethazine Hci 50 mg/mL | HF | 1 ml | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Promethazine Hydrochloride Injection — that fall in the same broad treatment class (antihistamines - 1st generation) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Promethazine Hydrochloride Injection shortage FAQs
Is Promethazine Hydrochloride Injection in shortage?
Why is Promethazine Hydrochloride Injection in shortage?
Which products are affected?
When will Promethazine Hydrochloride Injection be available again?
Can I still get Promethazine Hydrochloride somewhere?
What should I do if I take Promethazine Hydrochloride Injection?
Still have a question about the Promethazine Hydrochloride Injection shortage?
Ask a pharmacist about this shortage →View Promethazine Hydrochloride Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.